Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T111
- Development stage
- Preclinical
- Lead developer
- Portland State University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
T111 is a novel, preclinical-stage acridone-based antimalarial candidate developed by Portland State University in collaboration with the Department of Veterans Affairs and the Walter Reed Army Institute of Research. It targets the cytochrome b component of the parasite's mitochondrial electron transport chain (specifically the cytochrome bc1 complex), with a mechanism distinct from that of atovaquone. T111 exhibits potent, multi-stage activity against the liver (including dormant hypnozoites), blood (both asexual and sexual), and mosquito stages of Plasmodium parasites, offering potential as a single-dose radical cure and transmission-blocking agent.
- Other names
- acridone antimalarial candidate
02
Targets
CYTB (Plasmodium falciparum cytochrome bc1 complex (qi site))bc1 complex (Cytochrome bc1 complex (plasmodium))
Beyond the preview
Go deeper on T111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T111.